×
About 1,848 results

ALLMedicine™ Apraxia Center

Research & Reviews  699 results

Methylphenidate in Childhood Apraxia of Speech
https://clinicaltrials.gov/ct2/show/NCT05185583

Jan 11th, 2022 - This is a randomised, double-blind, placebo-controlled, two-period crossover proof-of-concept trial of methylphenidate (MPH) for children with childhood apraxia of speech (CAS). 24 children aged 6 to 12 years with CAS will be recruited. If childre...

Praxis deficits in patients with Parkinson's disease.
https://doi.org/10.1002/alz.058491
Alzheimer's & Dementia : the Journal of the Alzheimer's A... Rounis E

Jan 1st, 2022 - Limb apraxia has been described in several neurological disorders including Parkinson's disease (Leiguarda and Marsden, 2000) and may predict progression to Alzheimer's dementia in patients with mild cognitive impairment. Our aim was to study pres...

De novo pathogenic variant in SETX causes a rapidly progressive neurodegenerative disor...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684165
Acta Neuropathologica Communications; Hadjinicolaou A, Ngo KJ et. al.

Dec 20th, 2021 - Pathogenic variants in SETX cause two distinct neurological diseases, a loss-of-function recessive disorder, ataxia with oculomotor apraxia type 2 (AOA2), and a dominant gain-of-function motor neuron disorder, amyotrophic lateral sclerosis type 4 ...

Clinical Manifestations and Biomarkers in Amyotrophic Lateral Sclerosis Type 4 and Other Inherited Neurological Disorders of RNA Processing
https://clinicaltrials.gov/ct2/show/NCT04394871

Dec 16th, 2021 - Objective: Amyotrophic lateral sclerosis type 4 (ALS4) is an inherited form of motor neuron disease caused by mutation in the senataxin (SETX) gene. The main goal of this study will be to collect clinical and molecular biomarkers from patients wit...

The reliability and validity of the Turkish version of the apraxia screen of TULIA in m...
https://doi.org/10.1080/09638288.2021.2003447
Disability and Rehabilitation; Yıldız Z, Doymaz F et. al.

Dec 14th, 2021 - The study was aimed to analyze the psychometric properties of the Turkish version of the Apraxia Screen of TULIA (T-AST). A total of 112 patients with multiple sclerosis (MS) were included in the study. T-AST tasks were performed once while record...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  18 results

Methylphenidate in Childhood Apraxia of Speech
https://clinicaltrials.gov/ct2/show/NCT05185583

Jan 11th, 2022 - This is a randomised, double-blind, placebo-controlled, two-period crossover proof-of-concept trial of methylphenidate (MPH) for children with childhood apraxia of speech (CAS). 24 children aged 6 to 12 years with CAS will be recruited. If childre...

Clinical Manifestations and Biomarkers in Amyotrophic Lateral Sclerosis Type 4 and Other Inherited Neurological Disorders of RNA Processing
https://clinicaltrials.gov/ct2/show/NCT04394871

Dec 16th, 2021 - Objective: Amyotrophic lateral sclerosis type 4 (ALS4) is an inherited form of motor neuron disease caused by mutation in the senataxin (SETX) gene. The main goal of this study will be to collect clinical and molecular biomarkers from patients wit...

Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech
https://clinicaltrials.gov/ct2/show/NCT01818661

Nov 8th, 2021 - Apraxia of Speech (AOS) is a disorder of speech motor planning and/or programming that affects the production of speech, characterized by slow speaking rate, abnormal prosody and distorted sound substitutions, additions, repetitions and prolongati...

App Based Dexterity Training in Multiple Sclerosis
https://clinicaltrials.gov/ct2/show/NCT03369470

Sep 1st, 2021 - Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system and the most common cause of non-traumatic disability in young adults (Kamm et al. 2014; Vanbellingen & Kamm, 2016). It is a heterogeneous disease, which is as...

Apraxia in Parkinson's Disease Patients With Deep Brain Stimulation
https://clinicaltrials.gov/ct2/show/NCT04725773

Jun 7th, 2021 - This will be a pilot study designed to assess the safety and feasibility of an apraxia testing protocol in chronically implanted PD DBS patients. We hypothesize that apraxia testing in the DBS ON and OFF states will be a safe and well-tolerated te...

see more →

News  12 results

Inhaled Heroin Tied to 'Peculiar, Often Catastrophic' Brain Damage
https://www.medscape.com/viewarticle/899079

Jul 9th, 2018 - "Chasing the dragon" (CTD) — a method of inhaling heroin in which users heat heroin over aluminium foil with a lighter and then chase the fumes — is growing in popularity and may lead to "peculiar and often catastrophic brain complications," new r...

Alemtuzumab Linked to CNS Inflammation
https://www.medscape.com/viewarticle/875002

Jan 26th, 2017 - Two cases of what is suggested to be "the first recognised cases of severely exacerbated CNS [central nervous system] inflammation after alemtuzumab therapy in multiple sclerosis" have been published. Writing in a letter in the February issue of T...

Fourth PML Case With Tecfidera in MS Calls for Vigilance
https://www.medscape.com/viewarticle/856148

Dec 17th, 2015 - After a fourth case of progressive multifocal leukoencephalopathy (PML) linked to the multiple sclerosis (MS) drug dimethyl fumarate (Tecfidera, Biogen), it is becoming more widely accepted that even the "safer" immunosuppressant agents may cause ...

Fourth PML Case With Tecfidera in MS Calls for Vigilance
https://www.staging.medscape.com/viewarticle/856148

Dec 17th, 2015 - After a fourth case of progressive multifocal leukoencephalopathy (PML) linked to the multiple sclerosis (MS) drug dimethyl fumarate (Tecfidera, Biogen), it is becoming more widely accepted that even the "safer" immunosuppressant agents may cause ...

see more →

Patient Education  9 results see all →